

LISTA DE LUCRĂRI

CS I dr. Stanciu Adina Elena

LUCRĂRI ȘTIINȚIFICE PUBLICATE ÎN REVISTE INDEXATE ÎN WEB OF SCIENCE

1. Bolovan LM, Panait ME, Busca A, **Stanciu AE**, Chiriac D, Mihalcea CE, Hotnog CM, Georgescu MT, Voinea SC, Prunoiu VM, Brasoveanu LI, Gales LN. Variation in Immune and Inflammatory Blood Markers in Advanced Melanoma Patients Treated with PD-1 Inhibitors: A Preliminary Exploratory Study. *Biomedicines*. 2025;13(6):1378. doi: 10.3390/biomedicines13061378.
2. Bolovan LM, Panait ME, Mihaila M, Busca A, **Stanciu AE**, Bostan M, Brasoveanu LI, Hotnog CM. Modulation of the Therapeutic Resistance in SK-MEL-24 Human Melanoma Cells by Combined Treatments. *Appl Sci-Basel*. 2025;15(19):10703. <https://doi.org/10.3390/app151910703>.
3. Gherghe M, Mutuleanu MD, Suta TL, Micu L, **Stanciu AE**, Ionescu SO, Cirimbei C, Paun DL, Jercan A, Badelita SN, Coriu D. Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters. *Diagnostics* 2025;15(4):482. doi: 10.3390/diagnostics15040482.
4. **Stanciu AE**, Bolovan ML, Zamfir-Chiru-Anton A, Voiosu C, Dabla PK, Stanciu MM, Serdarevic N, Gherghe M. The Interplay Between High Cumulative Doses of Radioactive Iodine and Type 2 Diabetes Mellitus: A Complex Cardiovascular Challenge. *Int J Mol Sci*. 2024;26(1):37. doi: 10.3390/ijms26010037.
5. **Stanciu AE**, Hurduc A, Stanciu MM, Gherghe M, Gheorghe DC, Prunoiu VM, Zamfir-Chiru-Anton A. Portrait of the Inflammatory Response to Radioiodine Therapy in Female Patients with Differentiated Thyroid Cancer with/without Type 2 Diabetes Mellitus. *Cancers (Basel)*. 2023;15(15):3793. doi: 10.3390/cancers15153793. PMID: 37568611; PMCID: PMC10417100.
6. Gheorghe DC, Enculescu A, **Stanciu AE**, Epure V, Zamfir-Chiru-Anton A. Eustachian Tube Teratoma: A Rare Entity. *Clin Pathol*. 2023;16:2632010X231195231. doi: 10.1177/2632010X231195231. PMID: 37599665; PMCID: PMC10436987.
7. Bolovan LM, Ceausu M, **Stanciu AE**, Panait ME, Busca A, Hotnog CM, Bleotu C, Gales LN, Georgescu MT, Prunoiu VM, Brasoveanu LI, Voinea SC. Correlation Studies between S100 Protein Level and Soluble MIA or Tissue MelanA and gp100 (HMB45) Expression in Cutaneous Melanoma. *J Pers Med*. 2023;13(6):898. doi: 10.3390/jpm13060898. PMID: 37373887; PMCID: PMC10305456.
8. Gherghe M, Mutuleanu MD, **Stanciu AE**, Irimescu I, Lazar AM, Toma RV, Trifanescu OG, Anghel RM. Quantitative Assessment of Treatment Response in Metastatic Breast Cancer Patients by SPECT-CT Bone Imaging-Getting Closer to PET-CT. *Cancers (Basel)*. 2023;15(3):696. PMID: 36765651; PMCID: PMC9913230 <https://doi.org/10.3390/cancers15030696>.
9. Gherghe M, Lazar AM, Mutuleanu MD, Bordea CI, Ionescu S, Mihaila RI, Petroiu C, **Stanciu AE**. Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact? *Cancers (Basel)*. 2022;15(1):207. <https://doi.org/10.3390/cancers15010207> PMID: 36612202; PMCID: PMC9818586.
10. Gheorghe DC, **Stanciu AE**, Zamfir-Chiru-Anton A, Doru O, Epure V. Moebius syndrome-Case report. *Clin Case Rep*. 2022;10(12):e6715. PMID: 36523389 <https://doi.org/10.1002/ccr3.6715>
11. Gherghe M, Lazar AM, **Stanciu AE**, Mutuleanu MD, Sterea MC, Petroiu C, Gales LN. The New Radiolabeled Peptide ^{99m}TcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs? *Cancers* 2022;14(11):2725. <https://doi.org/10.3390/cancers14112725>
12. **Stanciu AE**, Stanciu MM, Zamfirescu A, Gheorghe DC. Cardiovascular Effects of Cumulative Doses of Radioiodine in Differentiated Thyroid Cancer Patients with Type 2 Diabetes Mellitus. *Cancers* 2022;14(10):2359. <https://doi.org/10.3390/cancers14102359>
13. **Stanciu AE**, Verzia A, Stanciu MM, Zamfirescu A, Gheorghe DC. Analysis of the Correlation between the Radioactive Iodine Activity and Neutrophil-to-Lymphocyte Ratio in Patients with Differentiated Thyroid Cancer. *Cancers* 2022;14(8):1899. <https://doi.org/10.3390/cancers14081899>
14. Gherghe M, Lazar AM, Mutuleanu MD, **Stanciu AE**, Martin S. Radiomics Analysis of [¹⁸F]FDG PET/CT Thyroid Incidentalomas: How Can It Improve Patients' Clinical Management? A Systematic Review from the Literature. *Diagnostics* 2022;12(2):471. <https://doi.org/10.3390/diagnostics12020471>

15. Gherghe M, Mutuleanu M.D, **Stanciu AE**, Irimescu I, Lazar A, Bacinschi X, Anghel RM. Quantitative Analysis of SPECT-CT Data in Metastatic Breast Cancer Patients—The Clinical Significance. *Cancers* 2022; 14(2):273. <https://doi.org/10.3390/cancers14020273>
16. Lete C, López-Iglesias D, García-Guzmán JJ, Leau SA, **Stanciu AE**, Marin M, Palacios-Santander JM, Lupu S, Cubillana-Aguilera L. A Sensitive Electrochemical Sensor Based on Sonogel-Carbon Material Enriched with Gold Nanoparticles for Melatonin Determination. *Sensors* 2022; 22(1):120. <https://doi.org/10.3390/s22010120>
17. Gheorghe DC, Stanciu MM, Zamfirescu A, **Stanciu AE**. TNF- α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis. *Cancers* 2021;13(14):3609. doi: 10.3390/cancers13143609. PMID: 34298820.
18. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Gherghe M, Hainarosie R, Furtunescu FL, Gheorghe DC. Clinical significance of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in the first phase of burn trauma evolution. *Exp Ther Med* 2021;22(4): 1113. doi: 10.3892/etm.2021.10547.
19. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Gherghe M, Hainarosie R, Furtunescu FL and Gheorghe DC: Role and dynamics of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in burn patients. *Exp Ther Med* 2021;22(4):1062. PMID: 34434276. doi: 10.3892/etm.2021.10496.
20. Serdarevic N, Dabla P, **Stanciu AE**. Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression. *Ind J Clin Biochem* 2021;36(2):151-158. PMID: 33867705. doi: 10.1007/s12291-019-0818-6.
21. Simion L, Stanculeanu D, Capsa Cristina M, **Stanciu A**, Stefan Cristina D. Highlights from the IOB Conference on Cancer, 20-22 May 2021 and the new research vision of The Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania. *ecancer* 2021;15:ed114. <https://doi.org/10.3332/ecancer.2021.ed114>
22. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Pantea-Stoian A, Nitipir C, Gheorghe DC. Serum melatonin is inversely associated with matrix metalloproteinase-9 in oral squamous cell carcinoma. *Oncol Lett.* 2020;19(4):3011–3020.doi:10.3892/ol.2020.11392.
23. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Stoian AP, Jinga V, Nitipir C, Bucur A, Pituru TS, Arsene AL, Dragoi CM, Hainarosie R, Nicolae AC, Gherghe M, Gheorghe DC, Spandidos DA, Tsatsakis A, Papisavva M, Drakoulis N. Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma. *Oncol Lett.* 2020;19(2):1537–1543. doi: 10.3892/ol.2019.11215
24. Dan SA, Bratu OG, Marcu DR, **Stanciu AE**, Gherghiceanu F, Ionita-Radu F, Bungau S, Stanescu AMA, Mischianu D. Underactive bladder - an underestimated entity. *J Mind Med Sci.* 2020; 7(1):23–28. DOI:10.22543/7674.71.P2328.
25. **Stanciu AE**, Popescu M, Gheorghe DC. Idiotype-specific intravenous immunoglobulin kappa free light chain deficiency. *Hum Vaccin Immunother.* 2019;15(5):1123–1125. doi: 10.1080/21645515.2019.1572411. PMID: 30676854
26. **Stanciu AE**. Cytokines in heart failure. *Adv Clin Chem.* 2019;93:63–113. doi: 10.1016/bs.acc.2019.07.002. PMID:31655733.
27. Nitipir C, Neagu AM, Iaciu C, Barbu MA, Popescu BC, Orlov C, Popa AM, Constantinescu R, Pietrosanu C, Pituru S, Hainarosie R, Pantea Stoian AM, **Stanciu AE**. New biomolecules for the treatment of Disseminated Intravascular Coagulation. *Rom Biotech Lett.* 2019;24(4):580–585. doi: 10.25083/rbl/24.4/580.585.
28. Nitipir C, Barbu MA, Orlov C, **Stanciu AE**, Popa AM, Hainarosie R, Pituru S, Arsene AL, Pantea Stoian A. Type II Diabetes Mellitus - Associated Risk Factor in the Onset and Evolution of Digestive Tract Carcinoma. *Rom Biotech Lett.* 2019;24(1):140–146. doi: 10.25083/rbl/24.1/140.146. WOS:000463708100016 (IF: 0.765)
29. **Stanciu AE**, Stanciu MM, Vatasescu RG. NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure. *Cytokine.* 2018;111:13–19. doi:10.1016/j.cyto.2018.07.037.
30. **Stanciu AE**, Vatasescu RG, Stanciu MM, Serdarevic N, Dorobantu M. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. *Cytokine.* 2018;103:63–68. doi: 10.1016/j.cyto.2017.12.026. PMID:29324263.
31. **Stanciu AE**, Sava F, Toldi G. A rare case of polyglandular autoimmune syndrome type IIIc with primary antibody failure. *Gynecol Endocrinol.* 2018;34(4):283–285. PMID: 29043872. doi: 10.1080/09513590.2017.1391775.
32. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC, Nitipir C. Serum matrix metalloproteinase-2 in head and neck squamous cell carcinoma is associated with tumor differentiation. *Rom Biotech Lett.* 2017;22(2):12419–12426.

33. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC. Imbalance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Promotes Invasion and Metastasis of Head and Neck Squamous Cell Carcinoma. *Clin Lab.* 2017;63(10):1613–1620. doi: 10.7754/Clin.Lab.2017.170339. PMID: 29035450.
34. Nitipir C, Niculae D, Orlov C, Barbu MA, Popescu B, Popa AM, Stoian Pantea AM, **Stanciu AE**, Galateanu B, Ginghina O, Papadakis GZ, Izotov BN, Spandidos DA, Tsatsakis AM, Negrei C. Update on radionuclide therapy in oncology (Review). *Oncol Lett.* 2017; 14: 7011–7015. doi: 10.3892/ol.2017.7141.
35. Koziorowski J, **Stanciu AE**, Gómez-Vallejo V, Llop J. Radiolabeled nanoparticles for cancer diagnosis and therapy. *Anticancer Agents Med Chem.* 2017;17(3):333–354. PMID: 26899184. doi: 10.2174/1871520616666160219162902.
36. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC. Serum Level of Matrix Metalloproteinase-9 in Patients with Head and Neck Squamous Cell Carcinoma. *Clin Lab.* 2016;62:1569–1574. doi:10.7754/Clin.Lab.2016.160139.
37. **Stanciu AE**, Hurduc AE, Stanciu MM. Effects of thyroid hormone withdrawal on natriuretic peptides during radioactive iodine therapy in female patients with differentiated thyroid cancer. *Scand J Clin Lab Invest.* 2016; 76(8): 626–631. doi: 10.1080/00365513.2016.1230883.
38. **Stanciu AE**, Serdarevic N, Hurduc AE, Stanciu MM. IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis. *Scand J Clin Lab Invest.* 2015;75(7):539–548. doi: 10.3109/00365513.2015.1057895.
39. Neacsu A, Contineanu M, Contineanu I, **Stanciu A**. Study on the Radical Species formed by Gamma Radiolysis of Alpha Aminobutyric Acid (α AMB). *Rev Chim-Bucharest.* 2014;65(3):306–310.
40. Sandru A, Panaitescu E, Voinea S, Bolovan M, **Stanciu A**, Cincea S, Blidaru A. Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma. *J Skin Cancer.* 2014;2014:843214. doi: 10.1155/2014/843214. PMID:25045539
41. **Stanciu AE**, Vatasescu RG, Stanciu MM, Iorgulescu C, Vasile AI, Dorobantu M. Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects. *Clin Biochem.* 2013;46(3):230–234. PMID:23159290. doi: 10.1016/j.clinbiochem.2012.11.002.
42. Serdarevic N, **Stanciu AE**. Comparison of Architect i2000 for determination of Sec with IMX determination of SCC with different methods. *Clin Lab.* 2013;59(9-10):1129–1133. PMID:24273937.
43. **Stanciu AE**. Radionuclides in targeted therapy of cancer. *Rev Roum Chim.* 2012;57(1):5–13.
44. Contineanu M, Neacsu A, Contineanu I, **Stanciu AE**. Kinetics of the thermal disappearance of radicals formed during the radiolysis of ammonium paramolybdate (APMO). *Rev Roum Chim.* 2012;57(11):937–945.
45. Contineanu M, Contineanu I, Neacsu A, **Stanciu AE**. EPR study of paramagnetic centers in gamma irradiated polycrystalline ammonium paramolybdate (APMO) and ammonium parawolframate (APW). *Rev Roum Chim.* 2011;56(12):1155–1162.
46. Contineanu M, **Stanciu AE**, Neacsu A. Thermal annealing kinetics of radicals formed by the radiolysis in polycrystalline solid state of sodium wolframate. *Rev Roum Chim.* 2010;55(8):467–474.
47. **Stanciu AE**. The importance of tumor markers in oncology. *Rev Romana Med Lab.* 2008;2(11):57–61.

LUCRĂRI ȘTIINȚIFICE PUBLICATE ÎN REVISTE INDEXATE BDI ȘI ÎN ALTE REVISTE DE SPECIALITATE CU ISSN

1. Dabla PK, Upreti K, Singh D, Singh A, Puri V, **Stanciu AE**, Serdarevic N, Gruson D. Anti-epileptic medication induced disturbed calcium-vitamin D metabolism: A behavioral analysis using association rule mining technique. *World J Exp Med* 2025; 15(3): 104799. doi: 10.5493/wjem.v15.i3.104799
2. Serdarevic N, Curlin M, Dautbasic A, **Stanciu AE**, Pradeep D, Durak-Nalbantik A. Changes of TSH, FT3 and FT4 levels in patients with hyperthyroidism. *Health Bulletin.* 2024; 10(1):94-107. <https://hrcak.srce.hr/317553>
3. Serdarevic N, **Stanciu AE**, Begic L, Uncanin S. Serum Uric Acid Concentration in Patients with Cerebrovascular Disease (Ischemic Stroke and Vascular Dementia). *Med Arch.* 2020;74(2):95-99. doi: 10.5455/medarh.2020.74.95-99
4. Neacsu A, **Stanciu AE**, Contineanu M, Gheorghe D. Effect of gamma irradiation on NaVO₃ in polycrystalline solid state. *Chem Rep.* 2020;2(1):124-131. DOI: [10.25082/CR.2020.01.002](https://doi.org/10.25082/CR.2020.01.002)
5. Gheorghe DC, Zamfir-Chiru-Anton A, Ene LE, **Stanciu AE**. Piriform sinus fistula management approach – our experience. *Ro Med J.* 2020;67(1):99-101. DOI: 10.37897/RMJ.2020.1.19
6. Gheorghe DC, Zamfir-Chiru-Anton A, Ene LE, **Stanciu AE**. Hunter syndrome revisited. *Ro Med J.* 2020;67(1):87-89. DOI: 10.37897/RMJ.2020.1.16

7. Gheorghe DC, Zamfir-Chiru-Anton A, Ene LE, **Stanciu AE**. Hairy polyp of the rhinopharynx – a rare and unrecognized entity. *Ro J Med Pract*. 2020;15(1):112-114. DOI: 10.37897/RJMP.2020.1.21
8. **Stanciu AE**, Serdarevic N, Stanciu MM, Mazilu L, Bratu O, Gheorghe M, Voinea SC, Gheorghe DC. Comparative evaluation of the bladder tumor-associated antigen, urinary bladder cancer antigen, tissue polypeptide specific antigen and voided urine cytology in early detection of primary bladder tumors. *Rev Chim (Bucharest)*. 2019;70(12):4514-4518. <https://doi.org/10.37358/RC.19.12.7786>.
9. Zamfir-Chiru-Anton A, Ulici A, **Stanciu AE**, Gheorghe DC. Atypical acute otomastoiditis - clinical case. *Ro J Med Pract*. Vol 13, Nr.1 (54), 2018. DOI: 10.37897/RJMP.2018.1.9
10. Zamfir-Chiru-Anton A, **Stanciu AE**, Gheorghe DC. Cricoid malformation and endolaryngeal submucosal drilling - a possible technique. *J Med Life*. 2017;10(3):194-196. PMID:29075350
11. Zamfir-Chiru-Anton A, **Stanciu AE**, Gheorghe DC. Osteomyelitis of the mandible with pseudotumoral manifestation. *Ro J Med Pract*. 2016; vol 11; Nr.2(45): 199-202. DOI: 10.37897/RJMP.2016.2.16
12. Zamfir-Chiru-Anton A, **Stanciu AE**, Gheorghe DC. Implications of melatonin in etiopathogenesis and treatment of autistic spectrum disorders. *Rom Med J*. 2016; vol. LXIII, Nr.2: 111-114. DOI: 10.37897/RMJ.2016.2.3
13. Gheorghe DC, Ulici A, **Stanciu AE**, Zamfir-Chiru-Anton A. Bilateral external ear canal osteomas - discussion on a clinical case. *J Med Life*. 2016;9(4). doi: 1022336/jml.2016.0420. PMID: 27928451
14. Contineanu M, **Stanciu AE**, Contineanu I, Neacsu A. Thermal disappearance kinetics of radicals formed during radiolysis in polycrystalline solid state of sodium wolframate dihydrate. *South Braz J Chem*. 2010; 18(18):49-64. doi: 10.48141/SBJCHEM.v18.n18.2010.51_2010
15. Busca A, Birtoiu A, Diaconescu A, **Stanciu A**, Stafidov N, Militaru M. Estrogen and progesterone in mammary tumors of bitch and cat / Estradiolul si progesteronul in tumorile mamare la catea si pisica. *Romanian Journal of Comparative Oncology* 2007; Nr.13:877-85. ISSN: 1584-6547.
16. Stanciu M, Faur D, Boev A, **Stanciu A**. ECG Measurement and Acquisition System for Heart Rate Variability Analysis. *Annals of the University of Craiova – Electrical Engineering Series* 2007;II(31):6–9. ISSN:1842-4805.
17. **Stanciu A**. Compararea testelor BTA si UBC cu citologia urinara spontana in diagnosticul si managementul cancerului de vezica. *Revista Romana de Laborator Medical* 2006; Anul I, Nr.2:32-8. ISSN 1841-866X
18. **Stanciu A**, Stanciu M. Optical Fiber Sensors in Nuclear Plants. *Electrotehnica - Electronica – Automatica (EEA)* 2005;53(4):15-20. ISSN: 1582–5175.
19. **Stanciu A**, Stanciu M. Influenta radiatiilor ionizante asupra organismelor vii. *Electronica Aplicata*. 2005; Anul VII, Nr. 37, Februarie – Martie:22–25. ISSN: 1454-2889.
20. **Stanciu AE**. Aplicatii clinice ale markerilor tumorali PSA total si PSA liber / Clinical applications of total PSA and free PSA tumor markers. *Rev Romana Med Lab*. 2005;1(1):33–38. ISSN: 1841-6624
21. Stanciu M, **Stanciu A**. Biosenzor cu fibre optice pentru masurarea concentratiei antigenului specific prostatic. *ATEE-IEEE* 2004. [indexed thorough Thomson-Reuters ISI-CPCI].
22. **Stanciu A**, Stafidov N, Stanciu M. Rolul markerilor tumorali PSA total si PSA liber in discriminarea intre hiperplazia prostatica benigna si cancerul de prostata. *Revista Romana de Oncologie* 2003;40(1):39–44
23. Fumarel R, Albert P, Hurduc A, Stafidov N, **Stanciu A**, Manolescu N, Moraru V, Terbea I. Marcarea radioactivă a metotrexatului cu izotopul ^{99m}Tc în vederea monitorizării scintigrafice în timp real a parametrilor chimioterapiei fotostimulate (PSChT*). Partea a II-a. *Revista Romana de Oncologie* 2003;39 (1-2):97-109.
24. Fumarel R, Albert P, Stafidov N, **Stanciu A**, Hurduc A, Manolescu N, Terbea I, Moraru V, Negoita V. Marcarea radioactivă a metotrexatului cu izotopul ^{99m}Tc în vederea monitorizării scintigrafice în timp real a parametrilor chimioterapiei fotostimulate (PChT). Partea I. *Revista Romana de Oncologie* 2000;37(1):62-7.
25. Contineanu M, **Stanciu A**. EPR study of radical species formed at the radiolysis of the second group selenites. *Rev Chim-Bucharest*. 2000;1(1-2):32–37. ISSN: 0034-7752
26. Stanciu M, Iliescu C, Pantelimon B, **Stanciu A**. Modelarea si simularea functionarii senzorilor de pH cu fibre optice. *Metrologie*. 1998; XIV(1):14–18. ISSN: 1220-546X.
27. Contineanu M, **Stanciu A**. Kinetics and mechanism of thermal annealing of the paramagnetic centres in γ irradiated BaCrO₄. *Analele Universitatii Bucuresti: Chimie* 1996; Anul V (serie noua): 43–49. ISSN: 1220-871X
28. Contineanu M, **Stanciu A**. Cinetica dispariției termice a speciilor radicalice formate la radioliza cromatilor din grupa a II-a. *Rev Chim-Bucharest*. 1996;47(2):139–142. ISSN: 0034-7752
29. Contineanu M, **Stanciu A**. ESR - Study of radical species formatted at the radiolysis of the second group chromates. *Analele Universitatii Bucuresti: Chimie* 1995; Anul IV (serie noua): 45–52. ISSN: 1220-871X

CAPITOLE DE CARTE PUBLICATE LA EDITURI INTERNAȚIONALE

1. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu M, Gheorghe DC. Chapter 8: *Impact of Thyroid Disease on Heart Failure*. In the book: *Advance Heart Failure and How it Impacts the Electrophysiologists*. Dr. John Kassotis (Ed.). InTech 2017. Pages 141-157. ISBN 978-953-51-2948-6, Print ISBN: 978-953-51-2947-9. DOI: 10.5772/66283.
2. **Stanciu AE**. Chapter 15: *Synthesis and Applications of Alpha/Beta Emitter-Labelled Nanoparticles*. In: *Isotopes in Nanoparticles. Fundamentals and Applications*. Edited by Jordi Llop, Vanessa Gomez-Vallejo, Peter Neil Gibson. Pan Stanford 2016. Pages 383-427. Print ISBN: 978-981-4669-08-5, eBook: 978-981-4669-09-2, 544 pg. <https://doi.org/10.1201/b19950>

CĂRȚI PUBLICATE LA EDITURI NAȚIONALE

1. Zamfir-Chiru-Anton A, **Stanciu AE**, Ulici A, Georgescu M, Gheorghe DC. *Melatonina*. Editura Universitara "Carol Davila", Bucuresti, 2019 (144 pg), ISBN:978-606-011-071-2.
2. Contineanu M, Neacsu A, **Stanciu AE**. *Defecte de Retea*. Editura Ars Docendi, Universitatea din Bucuresti, 2017 (140 pg). ISBN 978-973-558-981-3. http://arsdocendi.ro/t_carte.php?id_carte=254
3. **Stanciu AE**, Zamfir Chiru Anton A, Gheorghe DC. *Rolul metaloproteinazelor in cancerele de cap si gat*. Editura Pro Universitaria, Colectia Medicina, Bucuresti, 2015 (138 pg), ISBN: 978-606-26-0445-5. <http://www.prouniversitaria.ro/carte/rolul-metaloproteinazelor-in-cancerele-de-cap-si-gat>
4. **Stanciu AE**, Carageorgheopol A, Badiu C. *Markeri tumoralii si endocrini. Ghid practic*. Editura Universitara "Carol Davila", Bucuresti, 2014 (156 pg), ISBN: 978-973-708-745. <https://editura.umfcd.ro/markeri-tumoralii-i-endocrini/>
5. **Stanciu A**, Contineanu M, Stanciu M. *Actiunea radiatiilor ionizante asupra sistemelor biologice*. Editura Electra, Bucuresti, 2004 (193 pg), ISBN: 973-7728-26-2. <http://mail.agir.ro/carte/actiunea-radiatiilor-ionizante-asupra-sistemelor-biologice-112185.html>
6. Stanciu M, **Stanciu A**. *Senzori chimici si biochimici cu fibre optice*. Editura Electra, Bucuresti, 2003 (183 pg). ISBN: 973-8067-92-8.

COMUNICĂRI ȘTIINȚIFICE LA CONFERINȚE INTERNAȚIONALE

1. **Stanciu AE**. Speaker la International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Live Webinar 17.09.2025 cu titlul: *External Quality Control: a useful and necessary instrument in daily routine for the professionsts in clinical laboratories*. Prezentare and Q&A: „Key Aspects of Harmonization and External Quality Assessment in Tumor Marker Testing” https://www.aacb.asn.au/AACB/AACB/Events/Event_Display.aspx?EventKey=IFCC170925
2. **Stanciu AE**, Bolovan M, Stanciu MM, Zamfirescu A. A distinct pattern of DNA damage from high-dose radioactive iodine therapy in patients with differentiated thyroid cancer with/without type 2 diabetes mellitus. The 49th FEBS Congress, Istanbul, Turkiye, July 5-9, 2025.
3. **Stanciu AE**, Bolovan M, Stanciu MM, Zamfirescu A. Insights into the association between radioactive iodine therapy and cardiovascular disease in differentiated thyroid cancer. IFCC WorldLab Congress 2024, Dubai, UAE, May 26-30, 2024. Clin Chim Acta. 2024; 558(Suppl.1). P1363. <https://doi.org/10.1016/j.cca.2024.118218>
4. **Stanciu AE**, Stoica R, Stanciu MM, Gluck G. Profiling of matrix metalloproteinases and their specific tissue inhibitors in urinary bladder cancer: A prospective study on early recurrence detection. IFCC WorldLab Congress 2024, Dubai, May 26-30, 2024. Clin Chim Acta. 2024; 558(Suppl.1). P0957. <https://doi.org/10.1016/j.cca.2024.118966>
5. **Stanciu AE**, Bolovan LM, Stanciu MM, Zamfirescu A. Handling of serial blood samples collected from differentiated thyroid cancer patients undergoing radioiodine therapy. WorldLab-EuroMedLab Roma 2023 – Rome, Italy, May 21-25, 2023. DOI 10.1515/cclm-2023-7058. Clin Chem Lab Med 2023; 61, Special Suppl, P1772, pp S1856, May 2023 (e-Poster)

6. **Stanciu AE**, Bolovan LM, Stanciu MM, Gherghe M. Radioactive iodine therapy induces tissue inhibitor of metalloproteinase-1 expression. WorldLab-EuroMedLab Roma 2023 – Rome, Italy, May 21-25, 2023. DOI 10.1515/ccim-2023-7039. Clin Chem Lab Med 2023; 61, Special Suppl, P0322, pp. S408, May 2023 (e-Poster)
7. **Stanciu AE**, Bolovan LM, Stanciu MM, Zamfirescu A. The interplay of peripheral circulating free DNA and platelet-to-lymphocyte ratio in patients with differentiated thyroid cancer with/without type 2 diabetes mellitus undergoing radioiodine therapy. ESMO Congress 2022, Paris 09-13.09.2022, France. Annals of Oncology 2022;33(suppl 7): S1296-S1297, DOI:[10.1016/j.annonc.2022.07.1730](https://doi.org/10.1016/j.annonc.2022.07.1730)
[https://www.annalsofoncology.org/article/S0923-7534\(22\)03581-5/fulltext](https://www.annalsofoncology.org/article/S0923-7534(22)03581-5/fulltext).
8. **Stanciu AE**, Bolovan LM, Lazar AM, Mutuleanu MD, Stanciu MM, Gales L, Zamfirescu A, Gherghe M. Growth/differentiation factor-15 from biomarker to target in cancer. Molecular Analysis for Precision Oncology Congress 2022 (MAP 2022), Amsterdam 14-16.10.2022, Netherlands. Annals of Oncology 2022; 33(suppl 8): S1383-S1430. DOI: <https://doi.org/10.1016/j.annonc.2022.09.038>
9. **Stanciu AE**, Bolovan M, Zamfirescu A, Stanciu MM, Panait ME. Mechanistic insights into the role of B cells in radioiodine therapy of differentiated thyroid cancer associated with type 2 diabetes mellitus. Immunotherapy Bridge and Melanoma Bridge 2021. 01-02.12.2021 (Oral Communication). J Transl Med 2022; 20(1):6. <https://doi.org/10.1186/s12967-022-03290-1>
10. **Stanciu AE**, Bolovan M, Zamfirescu A, Stanciu MM, Panait ME. TGF- β 1: A crucial mediator of radioiodine therapy induced anti-tumor immunity. Molecular Analysis for Precision Oncology Virtual Congress 2021. 07-09.10.2021. Annals of Oncology 2021; 32(56): S1365-S1366 <https://doi.org/10.1016/j.annonc.2021.08.2062>
11. **Stanciu AE**, Bolovan M, Frasineanu C, Stanciu MM, Verzia A, Zamfirescu A. Effects of high cumulative radioiodine dosage on cardiovascular disease in differentiated thyroid cancer patients with/without type 2 diabetes mellitus. Excellence in Oncology Care (EIOC) 2021. 21-23.10.2021. Dubai, UAE
12. **Stanciu AE**, Hurduc AE, Stanciu MM, Bolovan M, Zamfirescu A. TGF- β 1 and TNF- α : Antagonistic cytokines controlling extracellular matrix remodeling after radioactive iodine therapy for papillary thyroid carcinoma. Molecular Analysis for Precision Oncology Virtual Congress 2020. 9-10.10.2020. Annals of Oncology 2020; 31: S1229. DOI: <https://doi.org/10.1016/j.annonc.2020.08.2198>
13. **Stanciu AE**, Zamfir-Chiru-Anton A, Stanciu MM, Gheorghie DC. Reduction in serum melatonin level may promote head and neck squamous cell carcinoma invasion and metastasis via targeting matrix metalloproteinase-9. EuroMedLab 2019, 19-23 May, Barcelona, Spain. Clin Chim Acta 2019; 493 (Supplement1): S126-S127. <https://doi.org/10.1016/j.cca.2019.03.269>
14. **Stanciu AE**, Popescu M. Intravenous immunoglobulin as an idiotype vaccine? EuroMedLab 2019, 19-23 May, Barcelona, Spain. Clin Chim Acta 2019; 493 (Supplement1): S237. <https://doi.org/10.1016/j.cca.2019.03.490>
15. Bolovan M, Busca A, **Stanciu A**, Panait M, Sandru A, Voinea S, Cinca S. Immunoassay techniques for specific skin cancer biomarkers. European Biotechnology Congress 2019, April 11-13, Valencia, Spain. J Biotechnol 2019; 305(Supplement): S78. <https://doi.org/10.1016/j.jbiotec.2019.05.271>
16. **Stanciu AE**, Hurduc AE, Zamfirescu A, Stanciu MM. TGF- β and TNF- α : antagonistic cytokines controlling extracellular matrix remodeling after radioactive iodine therapy for papillary thyroid carcinoma. Excellence in Oncology Care Congress, 17-19.11.2019, Dubai, UAE.
17. Bolovan M, Cinca S, Busca A, **Stanciu AE**, Panaitescu E, Sandru A, Voinea S. Identifying the melanoma patients with high risk for metastasis. European Biotechnology Congress 2018, April 26-28, Athens, Greece. J Biotechnol 2018; 280: S74. DOI: 10.1016/j.jbiotec.2018.06.242
18. **Stanciu AE**, Sava F, Toldi G. A new case of polyglandular autoimmune syndrome type IIIc with primary antibody failure. 3rd International Primary Immunodeficiencies Congress, 08-10.11.2017, Dubai, UAE.
19. **Stanciu AE**, Panait ME, Hurduc AE, Zamfirescu A, Stanciu MM, Cinca S. Transforming growth factor-beta 1 is a major mediator of radioactive iodine therapy-induced anti-tumor immunity. 42nd FEBS Congress, 10-14.09.2017, Jerusalem, Israel. FEBS J 2017 284 (Suppl 1): 280-280. DOI: 10.1111/febs.14174.
20. **Stanciu AE**, Vatasescu RG, Iorgulescu C, Stanciu MM, Dorobantu M. Elevated CA-125 levels are associated with increased immune activation in coronary sinus blood samples of patients with chronic heart failure. 69th AACC Annual Meeting, 30.07-03.08.2017, San Diego, CA, USA. Clin Chem 2017;63(S10): S26-S26.
21. **Stanciu AE**, Vatasescu RG, Stanciu MM, Dorobantu M. Paroxysmal, but not persistent, atrial fibrillation is associated with increased levels of transforming growth factor beta1. 69th AACC Annual Meeting, 30.07-03.08.2017, San Diego, CA, USA. Clin Chem 2017;63(S10): S96-S96.

22. Bolovan M, Voinea S, Panaitescu E, **Stanciu A**, Busca A, Cinca S, Sandru A. Concomitant determination of MIA and S100 proteins as prognostic factors in cutaneous malignant melanoma. European Biotechnology Congress, 25-27.05.2017, Dubrovnik, Croatia. *J Biotechnol* 2017;256 (Suppl): S78-S78. DOI: 10.1016/j.jbiotec.2017.06.1066.
23. **Stanciu AE**, Hurduc AE, Zamfirescu A, Stanciu MM. Predictive value of tissue inhibitor of metalloproteinases-1 in response to radioiodine therapy. The 41st FEBS Congress, Sept. 03-08, 2016, Kusadasi, Turkey. *The FEBS Journal* 2016; 283 (Suppl. 1): 429–440 DOI: 10.1111/febs.13903. P-02.07.5-004.
24. **Stanciu AE**, Hurduc AE, Zamfirescu A, Stanciu MM. Radioiodine therapy induces tissue inhibitor of metalloproteinase-1 expression. UAE Cancer Congress 2016, Oct. 20-22, Dubai, Book of Proceedings, 2016.
25. **Stanciu AE**, Panait ME, Hurduc AE, Stanciu MM. Transforming growth factor-beta 1 is a major mediator of tissue responses to radioactive iodine therapy. 5th FEBS Advanced Lecture Course - Matrix Pathobiology, Signaling and Molecular Targets, FEBS-MPST 2015, Sept. 24-29, Rhodes, Book of Proceedings, P71, pp.129. Available from: <http://www.febs-mpst2015.upatras.gr/attachments/article/88/FEBS%202015.pdf>
26. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S. Utility of simultaneous measurement of three serum tumor markers in melanoma patients. *Melanoma and Immunotherapy Bridge* 2015, Dec 1-4, Naples, Italy. *J. Transl Med* 14(S1) · July 2016. DOI: 10.1186/s12967-016-0791-2.
27. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S. The significance of various cut-off levels of Melanoma Inhibitory Activity in evaluation of cutaneous melanoma patients. *Melanoma and Immunotherapy Bridge* 2015, Dec 1-4, Naples, Italy. *J Transl Med* 14(S1) · July 2016. DOI: 10.1186/s12967-016-0791-2.
28. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Melanoma Inhibitory Activity protein in malignant melanoma: is it useful? 12th EADV Spring Symposium, March 5-8, Valencia, 2015, Book of Proceedings, P036 e-Poster.
29. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Simultaneous determination of two serum tumor markers in assessing malignant melanoma patients. *Melanoma Bridge* 2014, Dec 3-6, Naples, Italy. *J Transl Med* 2015, **13**(Suppl 1):P9. doi:10.1186/1479-5876-13-S1-P9. PMID: PMC4315289.
30. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Clinical value of Melanoma Inhibitory Activity in stratifying malignant melanoma patients. *Melanoma Bridge* 2014, Dec 3-6, Naples, Italy. *J Transl Med* 2015, **13**(Suppl 1):P10. doi:10.1186/1479-5876-13-S1-P10. PMID: PMC4315275.
31. Sandru A, Voinea S, Panaitescu E, Bolovan M, **Stanciu A**, Cinca S, Blidaru A. Melanoma Inhibitory Activity and regional lymph node status in malignant melanoma patients. *Melanoma Bridge* 2014, Dec 3-6, Naples, Italy. *J Transl Med* 2015, **13**(Suppl 1):P11. doi:10.1186/1479-5876-13-S1-P11. PMID: PMC4315276.
32. **Stanciu AE**, Hurduc AE, Stanciu MM. Impact of short-term hypothyroidism after levothyroxine-withdrawal on N-Terminal pro-A-type and N-Terminal pro-B-type natriuretic peptides in patients with differentiated thyroid carcinoma. IFCC WorldLab Istanbul 2014, 22-26.06.2014, Istanbul, Turkey. *Clin Chem Lab Med* 2014, 52, Special Suppl, pp S783. DOI: 10.1515/cclm-2014-4022.
33. **Stanciu AE**, Hurduc AE, Sasareanu A, Stanciu MM. Differential changes in protease-antiprotease balance and serum levels of soluble tumor necrosis factor receptors during radioiodine therapy. 38th FEBS Congress, 06-11.07.2013, Saint Petersburg, Russia. *FEBS Journal Supplement* 2013, 280:PSW04.S16-194, pp. 338.
34. **Stanciu AE**, Sasareanu A, Hurduc A. Effects of radioiodine therapy on protease-antiprotease balance and serum levels of soluble tumor necrosis factor receptors in papillary thyroid carcinomas with/ without autoimmune thyroid diseases. 4th FEBS Advanced Lecture Course - Matrix Pathobiology, Signaling and Molecular Targets, FEBS-MPST 2013, Sept 26-Oct1, Kos, Book of Proceedings, P36, pp.103. Available from: <http://www.febs-mpst2013.upatras.gr/attachments/article/13/FEBS%202013.pdf>
35. **Stanciu A**, Sasareanu A, Hurduc A. Differential changes in protease-antiprotease balance and serum levels of soluble tumor necrosis factor receptors during radioiodine therapy in papillary thyroid carcinomas with/without autoimmune thyroid diseases. Scientific Writing Workshop: Workshop on Writing Research Articles and Proposals in Cancer Research. Oct 24-25, 2013, Brno. <http://www.recamo.cz/cz/akce/scientific-writing-workshop/>
36. **Stanciu AE**, Sasareanu A, Hurduc A. Effects of radioiodine therapy on extracellular matrix degradation in papillary thyroid carcinomas with/without autoimmune thyroid diseases. 22nd IUBMB and 37th FEBS Congress. 04-09.09.2012, Sevilla, Spain. *FEBS Journal* 2012, 279 (Suppl.1), P04-61, pp.104.
37. **Stanciu AE**, Sasareanu A, Hurduc A. Effects of radioiodine therapy on protease-antiprotease balance in papillary thyroid carcinomas with/without autoimmune thyroid diseases. 4th EFIS-EJI South Eastern European Immunology School - SEEIS 2012, Sept 20-23, Sarajevo, Book of Proceedings, pp.14.

38. **Stanciu AE**, Sasareanu A, Hurduc A, Zamfirescu A. Effects of radioiodine therapy on imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in papillary thyroid carcinomas with/without autoimmune thyroid diseases. 2012 AACC Annual Meeting, 15.07-19.07.2012, Los Angeles, CA, USA. Clin Chem 2012, 58(10), Supplement, C-118, pp.A124.
39. **Stanciu AE**, Panait M, Sasareanu A, Hurduc A, Zamfirescu A. Effects of radioiodine therapy on immune status in papillary thyroid carcinomas with/without autoimmune thyroid diseases. 2012 AACC Annual Meeting, 15.07-19.07.2012, Los Angeles, CA, USA. Clin Chem 2012, 58(10), Supplement, C-117, pp.A124.
40. **Stanciu AE**, Vatasescu R, Stanciu M, Dorobantu M. Immediate effects of radiofrequency catheter ablation for paroxysmal/persistent atrial fibrillation. 2012 AACC Annual Meeting, 15.07-19.07.2012, Los Angeles, CA, USA. Clin Chem 2012, 58(10), Supplement, A-01, pp.A2.
41. **Stanciu AE**, Vatasescu R, Iorgulescu C, Stanciu M, Dorobantu M. Immediate effects of cardiac resynchronization therapy on N-terminal pro-brain natriuretic peptide and systemic inflammation. ESC Congress 2011, 27-31.08.2011, Paris, France. Eur Heart J 2011, 32, 40-40, P474 in e-Library.
42. **Stanciu AE**, Vatasescu R, Iorgulescu C, Stanciu M, Dorobantu M. Immediate effects of cardiac resynchronization therapy. 2011 AACC Annual Meeting, 24-28.07.2011, Atlanta, GA, USA. Clin Chem 2011, 57(10), Supplement, C-12, pp. A99.
43. **Stanciu AE**, Gluck G, Neagoe L, Stanciu M, Sinescu I. Remodeling of extracellular matrix in early recurrence of superficial bladder cancer. 2011 AACC Annual Meeting, 24-28.07.2011, Atlanta, GA, USA. Clin Chem 2011, 57(10), Supplement, A-32, pp. A11.
44. **Stanciu AE**, Rosu A, Tache A, Gherghe M, Hurduc A. Recurrence assessment in papillary thyroid carcinoma associated with autoimmune thyroid diseases, after thyroidectomy and before radioiodine therapy. 2011 AACC Annual Meeting, 24-28.07.2011, Atlanta, GA, USA. Clin Chem 2011, 57(10), Supplement, E-109, pp. A207.
45. **Stanciu A**, Vatasescu R, Iorgulescu C, Stanciu M, Dorobantu M. Anti-inflammatory and anti-remodeling effects of cardiac resynchronization therapy in patients with chronic heart failure. 3rd FEBS Advanced Lecture Course - Matrix Pathobiology, Signaling and Molecular Targets, FEBS-MPST 2011, Sept 2-7, Spetses, Book of Proceedings, P32, pp.99. http://www.febsmpst2011.upatras.gr/attachments/article/83/PROCEEDINGS_FEBS-MPST_2011.pdf
46. **Stanciu AE**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Anti-inflammatory and anti-remodeling effects of Cardiac Resynchronization Therapy. 2010 AACC Annual Meeting, 25-29.07.2010, Anaheim, CA, USA. Clin Chem 2010; 56(6), Supplement, C-86, pp. A133.
47. **Stanciu AE**, Stafidov N, Hurduc A, Fumarel R, Cinca S. Serum cytokines profiling in well differentiated thyroid Carcinoma. 2010 AACC Annual Meeting, 25-29.07.2010, Anaheim, CA, USA. Clin Chem 2010, 56(6), Supplement, D-178, pp. A208.
48. Ionescu L, **Stanciu AE**, Trifanescu R. Pattern of cytokines in Graves' disease after treatment with methimazol. 2010 AACC Annual Meeting, 25-29.07.2010, Anaheim, CA, USA. Clin Chem 2010, 56(6), Supplement, B-49, pp. A68.
49. **Stanciu A**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Effects of Cardiac Resynchronization Therapy on left ventricle remodeling. Prezentare orală invitată. EFIS-EJI South Eastern European Immunology School - SEEIS 2010, Oct 2-4, Dubrovnik, Book of Proceedings, pp.17. <http://www.bnitm.de/seeis2010/Programme/SEEIS2010%20final.pdf>
50. **Stanciu AE**, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. Inflammatory Markers Remodeling after Cardiac Resynchronization Therapy. 2009 AACC Annual Meeting, 19-23.07.2009, Chicago, IL, USA. Clin Chem 2009, 55(6), Supplement, p. A-68.
51. **Stanciu AE**, Stafidov N, Gluck G, Sinescu I, Neagoe L, Stanciu M. A Comparison of Some Urine Biomarkers to Cytology and Cystoscopy in Patients with Recurrent Bladder Tumors. 2009 AACC Annual Meeting, 19-23.07.2009, Chicago, IL, USA. Clin Chem 2009, 55(6), Supplement, p. A-116.
52. **Stanciu AE**, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. Inflammatory markers in patients with heart failure. EUROMEDLAB 2009, 07-11.06.2009, Innsbruck, Austria. Clin Chem Lab Med 2009, 47, Special Supplement, pp.135.
53. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Neagoe L, Stanciu M. Clinical evaluation of some urine markers and comparison to urinary cytology and cystoscopy in patients with recurrent bladder tumors. EUROMEDLAB 2009, 07-11.06.2009, Innsbruck, Austria. Clin Chem Lab Med 2009, 47, Special Supplement, pp.135.

54. OT Greco, A Berruezo, P Castellant, RG Vatasescu, FZ Khan, A Meiltz, A Mihalcz, RJ Van Bommel, S Sideris, A Laish-Farkash, WPM Van Meerwijk, S Partemi, P Saravanan, FJ Lacunza Ruiz, G De Roest, AC Abreu, L Mont, D Tamborero, M Sitges, D Andreu, E Silva, J Brugada, E Orhan, M Fatemi, Y Etienne, V Valls-Bertault, JJ Blanc, C Iorgulaescu, A Vasile, D Constantinescu, **A Stanciu**, N Dumitrescu, M Dorobantu, PA Read, MS Virdee, CS Foldesi, M Nobuyoshi. The Predictors of Ventricular Arrhythmic Events after Cardiac Resynchronization Therapy. *Europace* 2009,11(2),NP-NP. DOI: <http://dx.doi.org/10.1093/europace/euq241>.
55. **Stanciu AE**, Stafidov N, Salageanu A, Dorobantu M, Vatasescu R, Stanciu M. Inflammatory Markers Involved in Patients Undergoing Cardiac Resynchronization Therapy. 2008 AACC Annual Meeting, 27-31.07.2008, Washington, DC, USA. *Clin Chem* 2008, 54(6), B-138, pp. 93.
56. Anghel R, Gruia I, Oprea L, Minea L, Bacinschi X, **Stanciu AE**. The monitoring of the apoptosis induction after boron neutron capture therapy in experimental hepatoma. 19th International Congress of Anti-Cancer Treatment, Paris, France, Feb 5-8, 2008. Proceedings of the ICACT 2008.
57. **Stanciu AE**, Stafidov N, Stanciu M. Biomarkers used in monitoring of patients with chronic heart failure. *Rev Romana Med Lab* 2007, vol.7, Nr.2, CB2, pp.19-20.
58. Glück G, Sinescu I, Stoica R, Dragoescu O, **Stanciu AE**, Stafidov N, Bogdan M, Stanciu M. BTA, UBC, TPS tumor markers, urinary cytology and cystoscopy in recurrent bladder tumors. *Urology* 2007;70(3) Supplement: 237. DOI: <http://dx.doi.org/10.1016/j.urology.2007.06.758>.
59. Glück G, Sinescu I, Stoica R, Dragoescu O, **Stanciu AE**, Stafidov N, Bogdan M, Stanciu M. BTA, UBC, TPS tumor markers, urinary cytology and cystoscopy bladder tumors. *Urology* 2006, 105 (1).
60. **Stanciu AE**, Stafidov N, Hurduc A, Albert P, Fumarel R. Biochemical markers (TSH, ANTI-TG, TG) complementarity with scynthigraphic exam in metabolic radiotherapy of thyroid cancer. *Rev Romana Med Lab* 2006, vol. 3, Nr.2, P15, pp.85-86.
61. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Dragoescu O, Stanciu M. Clinical evaluation of a few tumor markers (BTA Trak, UBC, TPS) and comparison to citology and cystoscopy in patients with recurrent bladder tumors. *Rev Romana Med Lab* 2006, vol.3, Nr.2, P16, pp.87-88.

COMUNICĂRI ȘTIINȚIFICE LA CONFERINȚE NAȚIONALE

1. **Stanciu AE**. Speaker – Prezentare: “Carbon Ion Radiotherapy in Triple Negative Breast Cancer, Exploiting Radiobiological Advantages for Preclinical Progress” la The 36th Annual Congress of the Romanian Society for Radiotherapy and Medical Oncology “Innovation and Progress in Oncology and Radiotherapy” (Research Session 1 – Dr. LASER Project, Round Table), Brasov, 09 – 11.10.2025
2. **Stanciu AE**, Bolovan M, Mihalcea C, Chiriac D, Zamfirescu A. Targeting TNFR2 in radioiodine therapy: a novel axis in immune-matrix remodeling in differentiated thyroid carcinoma. *Zilele Medicale si Stiintifice ale IOB*. 12 – 14.06.2025
3. Dumitran ID, Ivan CG, Marghidan CS, Preda M, Maglas L, Sorescu G, Popa C, **Stanciu AE**. Comparative analytical performance of tumor marker testing in Romania: insights from national EQA programs. *Zilele Medicale si Stiintifice ale IOB*. 12 – 14.06.2025
4. Dumitran ID, Ivan CG, Marghidan CS, Preda M, Maglas L, Sorescu G, Popa C, **Stanciu AE**. Identifying sources of analytical error in thyroid biomarker testing through external quality control. *Zilele Medicale si Stiintifice ale IOB*. 12 – 14.06.2025
5. Bolovan M, **Stanciu AE**, Panait ME, Busca A, Mihalcea C, Chiriac D, Hotnog CM, Voinea S, Gales LN, Brasoveanu LI Zamfirescu A. Correlation analyses between systemic inflammatory markers and circulating biomarkers in advanced melanoma patients treated with PD-1 inhibitors. *Zilele Medicale si Stiintifice ale IOB*. 12 – 14.06.2025
6. **Stanciu AE**, Bolovan M, Verzia A, Zamfirescu A. Dynamics of radioactive iodine blood concentration following therapy in patients with differentiated thyroid cancer. *Oncolog Hematolog*, Year XVIII, No. 67(2) 2024. IOB Conference Abstracts DOI: 10.26416/OnHe.67.2.2024. <https://www.medichub.ro/reviste-de-specialitate/oncolog-hematolog-ro/iob-conference-abstracts-id-9708-cmsid-68>
7. Dumitran ID, Dinulescu GC, Cirstea A, Sorescu G, Popa C, Ivan CG, **Stanciu AE**. Identification of potential errors in tumor marker daily routine testing using external quality control in the medical laboratories. *Oncolog Hematolog*, Year XVIII, No. 67(2) 2024. IOB Conference Abstracts DOI: 10.26416/OnHe.67.2.2024. <https://www.medichub.ro/reviste-de-specialitate/oncolog-hematolog-ro/iob-conference-abstracts-id-9708-cmsid-68>

8. **Stanciu AE.** Legal decision regarding the internal quality control (IQC) and external quality control (EQC) in the immunology department of the medical analysis laboratory. OBBCSSR Scientific Conference. Bucharest. February 2024
9. **Stanciu AE,** Bolovan M, Verzia A, Zamfirescu A. Molecular radiotherapy requires the evaluation of radioactivity in biological samples collected from cancer patients treated with different radiopharmaceuticals. Conferinta Zilele Medicale si Stiintifice ale IOB. 04-07 Mai 2023
10. Bolovan ML, Gales LN, **Stanciu AE,** Busca A, Panait ME, Brasoveanu LI. Dynamic variation of the T lymphocyte's subsets, B lymphocytes and NK cells during nivolumab therapy in cutaneous melanoma patients. Conferinta Zilele Medicale si Stiintifice ale IOB. 04-07 Mai 2023
11. **Stanciu AE.** Prediction models of lung cancer based on tumor markers. Lung Cancer Regional Conference. 03-04.09.2021
12. **Stanciu AE,** Bolovan LM, Frasineanu C, Stanciu MM, Verzia A, Tegus T, Nicorovici C, Dumitrescu A, Zamfirescu A. Cardiovascular risk assessment in patients with differentiated thyroid cancer undergoing radioiodine therapy. IOB Medical and Scientific Days. "The role of the tumor board in personalized medicine". 20-22.05.2021. Oncolog-Hematolog, Anul XV, 55(2), 2021. DOI: 10.26416/OnHe.55.2.2021
13. Kajanto L, Gherghe M, **Stanciu AE,** Stanculeanu D. Cancer therapy-induced cardiotoxicity: assessment by radionuclide imaging and molecular biomarkers. National Congress of Oncology. 03-04.09.2021. Poiana Brasov, Romania
14. **Stanciu AE,** Hurduc AE, Bolovan M, Stanciu M, Mihai M, Stoica R, Sinescu I. Diagnostic performance of a multi-biomarker panel for the non-invasive detection of bladder cancer. "Interdisciplinary Perspectives in Oncology" Conference. 27-29.09.2020
15. **Stanciu AE,** Stanciu MM, Gluck Gabriel, Sinescu I. Diagnostic performance of a multi-biomarker panel in bladder cancer. The 16th Conference of OBBCSSR, Bucharest, 10 November 2020
16. **Stanciu AE,** Stanciu MM, Gluck G, Sinescu I. Identification, using ROC curves, of the best combination of biomarkers for the primary assessment of bladder cancer. The 15th Conference of OBBCSSR, Bucharest, 9 November 2019.
17. **Stanciu AE,** Lazar VE, Alecsa GN, Sasareanu AM. The beneficial effects of Hyperbaric Oxygen Therapy from the point of view of laboratory medical analysis. The 15th Conference of OBBCSSR, Bucharest, 9 Nov. 2019
18. **Stanciu AE.** Could too much "good" HDL cholesterol be bad? The 14th Conference of OBBCSSR, Bucharest, 10 November 2018
19. **Stanciu AE,** Stanciu MM, Vatasescu RG. The concentration of CA 125 in serum from the coronary sinus reflects the severity of heart failure. The 14th Conference of OBBCSSR, Bucharest, 10 November 2018
20. **Stanciu AE,** Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC. Imbalance between matrix metalloproteinases and their tissue inhibitors is associated with metastatic spread via lymphatic pathways in head and neck squamous cell carcinomas. Institute of Oncology Conference. 17-19 May 2018. Oncolog-Hematolog.ro, XII. No.43 (2/2018), pp 31. DOI: 10.26416/OnHe.43.2.2018
21. **Stanciu AE,** Zamfir-Chiru-Anton A, Stanciu MM, Popescu CR, Gheorghe DC. Imbalance between matrix metalloproteinases and their tissue inhibitors in head and neck squamous cell carcinoma. Institute of Oncology Conference. 15-17 May 2017. Oncolog-Hematolog.ro, XI. No.39 (2/2017), pp 31
22. **Stanciu AE.** Errors in immunology department of medical analysis laboratory. The 13th National Conference of OBBCSSR. 12 November 2016, Bucharest.
23. **Stanciu AE,** Negoita V, Gruia MI, Bleotu C, Diaconu C, Botezatu A, Tica V, Ilie V, Florea R, Sorop A, Dima S, Popescu I. Alginate-encapsulated human pancreatic cancer cells for development of mouse models. Workshop "New methodologies and advanced nanomaterials for electrochemical biosensors". Faculty of Applied Chemistry and Materials Science. University Politehnica of Bucharest, 20 May 2016, Bucharest. <http://www.microbiosens.ro/index.php/workshop>
24. Bolovan M, Sandru S, Voinea S, **Stanciu A,** Busca A, Cincea S. Significance of MIA and S100 proteins in the evaluation of patients with cutaneous malignant melanoma. Conference of the Romanian Society for Radiotherapy and Medical Days of Institute of the Oncology, Bucharest, November 05-07, 2015, Book of Proceedings, P2, pp.83.
25. **Stanciu AE,** Sasareanu A, Hurduc A, Albert Paul. Immune status assessment in patients with papillary thyroid carcinoma associated with autoimmune thyroid diseases, after thyroidectomy and before radioiodine therapy. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology, Bucharest, November 17-19, 2011
26. **Stanciu AE,** Panait M, Sasareanu A, Hurduc A, Zamfirescu A, Albert P, Tegus T, Vaduva M, Nicorovici C, Dragomir D. Effect of radioiodine therapy on immune status of patients with papillary thyroid carcinoma with/without autoimmune thyroid disease. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology, Bucharest, November 17-19, 2011

27. **Stanciu AE**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Effects of resynchronization therapy. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology, Bucharest, November 18-20, 2010
28. **Stanciu AE**, Ionescu L, Trifanescu R. The immune status in Graves' disease and papillary thyroid cancer. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology, Bucharest, November 18-20, 2010
29. **Stanciu AE**. External quality assessment programmes for medical analysis laboratories. 6th OBBCSSR National Conference (Promoting quality in medical laboratory activity, legislation, certification, accreditation, external quality control, continuous professional training), Bucharest, October 24th, 2010
30. **Stanciu AE**, Stanciu M, Vatasescu R, Iorgulescu C, Dorobantu M. Effects of cardiac resynchronization therapy on neurohormones and cytokines levels. 5th Conference of the Romanian Association of Medical Laboratories with International Participation, Under the auspices of IFCC and EFCC, Mamaia, June 16-19, 2010
31. **Stanciu AE**, Stafidov N, Hurduc A. Pro and antiinflammatory cytokines in differentiated thyroid carcinoma. 5th Conference of the Romanian Association of Medical Laboratories with International Participation, Under the auspices of IFCC and EFCC, Mamaia, June 16-19, 2010
32. Ionescu L, **Stanciu AE**, Trifanescu R. Inflammatory profile of Graves' disease after treatment with methimazol and before surgical intervention. 5th Conference of the Romanian Association of Medical Laboratories with International Participation, Under the auspices of IFCC and EFCC, Mamaia, June 16-19, 2010
33. **Stanciu AE**. Role of free PSA biomarker to differentiate between benign prostatic hyperplasia and prostate cancer. 5th National Conference of OBBCSSR, Bucharest, October 25, 2009
34. **Stanciu AE**, Stafidov N. News in monitoring of bladder cancer. 5th National Conference of OBBCSSR, Bucharest, October 25, 2009
35. **Stanciu AE**. The importance of BNP biomarker measurement in diagnosis, staging and monitoring of patients with heart failure. 5th National Conference of OBBCSSR, Bucharest, October 25, 2009
36. **Stanciu AE**, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. Biomarkers used in monitoring of patients undergoing cardiac resynchronization therapy. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology Bucharest, Poiana Brasov, September 17-19, 2009
37. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Neagoe L, Stanciu M. The level of some urinary biomarkers, urinary cytology and cystoscopy in bladder tumor recurrences. Conference of Romanian Society for Radiotherapy and Medical Days of Institute of Oncology Bucharest, Poiana Brasov, September 17-19, 2009
38. **Stanciu AE**. Biomarkers in Chronic Heart Failure. Updates in Laboratory Medicine, Bucharest, 27 March, 2009
39. **Stanciu AE**. Some cytokines implications in patients with well differentiated thyroid cancer. Workshop "Radioisotopes & Biomolecules: A Partnership for the Early Diagnosis and Targeted Radiotherapy of Cancer", Bucharest, November 26-28, 2008
40. **Stanciu AE**, Stafidov N, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. The expression of biochemical markers in patients with chronic heart failure undergoing cardiac resynchronization therapy. VIASAN National Symposium - CEEX (Module I), Sinaia, September 28-30, 2008
41. **Stanciu AE**, Stafidov N, Salageanu A, Tucureanu C, Boghean R, Dorobantu M, Vatasescu R, Iorgulescu C, Stanciu M. Biomarkers used in monitoring of patients undergoing cardiac resynchronization therapy – 38th Annual Conference of Immunology, Busteni, September 24-26, 2008
42. **Stanciu AE**, Stafidov N. Some cytokines implications in patients with thyroid cancer – 38th Annual Conference of Immunology, Busteni, September 24-26, 2008
43. **Stanciu AE**, Stafidov N, Moise G. The expression of some cytokines in thyroid cancer. National Congress of Oncology and Medical Days of Institute of Oncology Bucharest, June 20-22, 2008
44. **Stanciu AE**, Stafidov N, Dorobantu M, Vatasescu R, Stanciu M. Biomarkers in cardiac resynchronization therapy. National Congress of Oncology and Medical Days of Institute of Oncology Bucharest, June 20-22, 2008
45. **Stanciu AE**. Tumor Markers. Actualities and Perspectives. ALMR Workshop, Bucharest, March 14th, 2008
46. **Stanciu AE**, Stafidov N, Salageanu A, Tucureanu C, Boghean R. Biochemical markers used for the evaluation of cardiac resynchronisation therapy in chronic heart failure patients. National Symposium of Excellence Medical Research, Sibiu, October 25-26, 2007
47. **Stanciu AE**, Stafidov N, Stanciu M. Biomarkers used in monitoring of patients with chronic heart failure. 3rd RAML Conference with International Participation, June 27-30, 2007
48. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Stanciu M. Tumor markers BTA, UBC, TPS act in urinary bladder cancer. The 2nd National Conference of OBBCSSR, Bucharest, Parliament Palace, November 4-5, 2006

49. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Stanciu M. Tumor markers BTA, UBC, TPS, urinary cytology and cystoscopy in early recurrences of bladder tumors. National Congress of Oncology – 16th Congress of SRRO, Bucharest, October 12-14, 2006
50. Dumitru M, Nicolaescu R, **Stanciu AE**, Dancus C, Radu M, Condrea I, Vasilescu M. HER-2 expression and EGFR in cervical tumors. National Congress of Oncology – 16th Congress of SRRO, Bucharest, Oct 12-14, 2006
51. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Stanciu M. New biomarkers: BTA, UBC, TPS, TNF- α . National Conference of Comparative Oncology with International Participation, Tulcea, September 22-23, 2006
52. Dumitru M, Nicolaescu R, **Stanciu AE**, Dancus C, Condrea I. Her-2 expression in cervical cancer. National Conference of Comparative Oncology with International Participation, Tulcea, September 20-23, 2006
53. Gluck G, Sinescu I, Stoica R, Dragoescu O, **Stanciu AE**, Stafidov N, Bogdan M, Stanciu M. BTA, UBC, TPS tumor markers, urinary cytology and cystoscopy in bladder tumors recurrence. XXIInd Congress of the Romanian Association of Urology ROMURO 2006, Bucharest, June 24-25 2006. Abstract published in Romanian Journal of Urology, vol.5, supplement, pp.32. ISSN: 1223-0650. CNCSIS: D-486
54. **Stanciu AE**, Stafidov N, Bogdan M, Gluck G, Sinescu I, Stoica R, Dragoescu O, Stanciu M. Clinical evaluation of a few tumor markers (BTA Trak, UBC, TPS) and comparison to cytology and cystoscopy in patients with recurrent bladder tumors. 2nd Conference of the Romanian Association of Medical Laboratories with International Participation, Timișoara, May 24-27, 2006
55. **Stanciu AE**, Stafidov N, Hurduc A, Albert P, Fumarel R. Biochemical markers (TSH, ANTI-TG, TG) complementarity with scynthigraphic exam in metabolic radiotherapy of thyroid cancer. 2nd Conference of the Romanian Association of Medical Laboratories with International Participation, Timișoara, May 24-27, 2006
56. **Stanciu AE**. Tumor and hormonal markers in metabolic radiotherapy of thyroid cancer. Symposium: Update in Laboratory Medicine, Hepatology and Transplantation Immunology, Fundeni Clinical Institute, Bucharest, March 31, 2006
57. **Stanciu AE**, Stafidov N. Relation between PSA concentration and prostate cancer. The 1st National Conference of OBBCSSR, Bucharest, Parliament Palace, November 5, 2005
58. Hurduc A, Albert P, **Stanciu AE**, Stafidov N, Fumarel R. Clinical and laboratory parameters in metabolic radiotherapy. National Congress of Oncology, Bucharest, Parliament Palace, June 23-25, 2005
59. Gluck G, Costache B, Sabau V, Sinescu I, Stafidov N, **Stanciu AE**. Diagnostic performance of a few tumor markers (BTA TRAK, UBC, TPS). A comparative study with cytology and cystoscopy for evaluation of the superficial bladder tumors recurrences. National Congress of Oncology, Bucharest, Parliament Palace, June 23-25, 2005
60. **Stanciu AE**, Stafidov N. A new tumor marker: BTA. National Congress of Oncology, Bucharest, Parliament Palace, June 23-25, 2005
61. **Stanciu AE**, Stafidov N, Stanciu M. Evaluation of tumor markers expression in diagnosis and development of bladder tumors. 1st Conference of the Romanian Association of Medical Laboratories, Sibiu, June 15-18, 2005
62. **Stanciu AE**. Tumor markers in advanced forms of neoplasm monitoring. Symposium: Update in Hepatology and Laboratory Medicine, Fundeni Clinical Institute, Bucharest, April 8, 2005
63. Stanciu M, **Stanciu AE**. Optical fiber biosensor for prostate specific antigen concentration measurement. ATEE 2004, The 4th Symposium on Advanced Topics in Electrical Engineering, Bucharest, Romania (CD-ROM), ISBN: 973-7728-31-9, November 25-26, 2004
64. **Stanciu AE**, Stafidov N, Stanciu M. Prostate cancer probability determination by means of total and free PSA tumor markers. The 34th National Conference of Immunology, Bucharest, September 16-17, 2004
65. Stanciu M, **Stanciu AE**. The measurement of PSA concentration by means of sensors with optical fibers. The 3rd Conference of Clinical Laboratory Foundation “Marcela Zamfirescu Gheorghiu”, Oradea, May 19-22, 2004
66. **Stanciu AE**, Stafidov N, Stanciu M. The performance of free PSA tumor marker in differentiating benign prostatic hyperplasia from prostate cancer. The 3rd Conference of Clinical Laboratory Foundation “Marcela Zamfirescu Gheorghiu”, Oradea-Băile Felix, May 19-22, 2004
67. **Stanciu AE**, Stafidov N, Stanciu M. The importance of total PSA and free PSA tumoral markers in prostate cancer diagnosis. Romanian National Conference of Oncology, Bucharest, May 14-15, 2004
68. **Stanciu AE**, Stafidov N, Stanciu M. The importance of total PSA and free PSA tumoral markers in oncological treatment dynamics for patients with prostate cancer. The 2nd Conference of Clinical Laboratory Foundation “Marcela Zamfirescu Gheorghiu”, Sovata, May 21-24, 2003
69. Albert P, Fumarel R, Savu M, **Stanciu AE**, Stafidov N, Hurduc A. The principles of photostimulated radiochemotherapy with cysplatin (CDDP-PSRChT). Romanian National Conference of Oncology, Bucharest, May 9-10, 2003
70. **Stanciu AE**, Stafidov N, Stanciu M. The tumoral markers utilization in monitoring of oncological treatment. Romanian National Conference of Oncology, Bucharest, May 9-10, 2003

71. **Stanciu AE**, Stafidov N. The correlation between total PSA and free PSA in diagnosis and management of prostate cancer. The 1st Congress of Clinical Laboratory Foundation “Marcela Zamfirescu Gheorghiu”, Mamaia, May 29-June 1, 2002
72. **Stanciu AE**, Stafidov N, Stanciu M. The importance of total PSA and free PSA tumoral markers in diagnosis and monitoring of prostate cancer. National Conference of Oncology, Bucharest, November 23-24, 2001
73. Fumarel R, Albert P, Hurduc A, Stafidov N, **Stanciu AE**. Scyntigraphic management of photostimulated chemotherapy. National Conference of Oncology, Bucharest, November 23-24, 2001
74. **Stanciu AE**, Stafidov N, Albert P. The PSA importance in monitoring of prostate cancer. The 1st National Congress of Nuclear Medicine with international participation, Bucharest, October 3-6, 2001
75. Albert P, Hurduc A, Stafidov N, **Stanciu AE**. Methotrexate radioactive labeling with ^{99m}Tc isotope. The 1st National Congress of Nuclear Medicine with international participation, Bucharest, October 3-6, 2001
76. Manoiu E, Gruber E, Panait M, Tache A, **Stanciu AE**, Stafidov N. The importance of immunofenotypic investigation in diagnosis and treatment of acute lymphoblastic leukemia at the children. Romanian Journal of Comparative Oncology, Annex, p. 24 - 25, 2000
77. **Stanciu AE**, Stafidov N, Manoiu E. Clinical applications of AFP and HCG tumor markers in testis cancer and choriocarcinomas. Romanian Journal of Comparative Oncology, Annex, p. 25 - 26, 2000
78. Stanciu M, **Stanciu AE**. Optical biosensor for prostate specific antigen (PSA) measurement. The 3rd Balkan Congress of Oncology, Poiana Braşov, September 10-14, 2000
79. **Stanciu AE**, Manoiu E, Stafidov N. The study of relation between ovarian cancer and breast cancer using some tumoral markers like: CA 125, HCG, CA 15 – 3. European Conference on Biomedical Research and Peace, Cypru, October 17-21, 1999
80. **Stanciu AE**, Manoiu E, Stafidov N. The clinical applications of CA 15 – 3 and CA 125 tumoral markers in management of treatment and of cancer disease evolution at patients with breast cancer. National Conference of Oncology, Bucharest, October 14-16, 1999
81. Stanciu M, Iliescu C, Pantelimon B, **Stanciu AE**. Modeling and simulation of pH sensors with optical fibers. The 6th National Symposium of Metrology, Bucharest, September 17-18, 1997
82. **Stanciu AE**, Stanciu M. New measurement methods in oncology: optical fiber immunosensors. National Conference of Oncology, Brasov, October 21-23, 1996
83. Manoiu E, Dragomir M, **Stanciu AE**. The surface markers utilization in diagnosis of leukemia cases at the children. National Conference of Oncology, Brasov, October 21-23, 1996
84. Manoiu E, **Stanciu AE**, Stafidov N, Iosub A, Balanescu I. Clinical applications of tumor markers in the breast cancer. The International Symposium of Comparative Oncology, Tulcea – Neptun, September 24-29, 1995
85. **Stanciu AE**, Draganescu M, Manoiu E, Stafidov N. HCG, tumoral marker in testis cancer. The International Symposium of Comparative Oncology, Tulcea – Neptun, September 24-29, 1995
86. **Stanciu AE**, Draganescu M, Manoiu E, Stafidov N. The clinical signification of HCG marker in testis cancer. Annual Scientific Session of the Institute of Oncology Bucharest, May 26-27, 1995
87. Contineanu M, **Stanciu AE**. Study of paramagnetic centres formed at the radiolysis of the second group chromates, using EPR technique. 7th National Conference of Physical – Chemistry, Bucharest, 21-23.09.1994

Data: 24.05.2026